The FDA provides details on the breakdown for the new Office of In Vitro Diagnostics and Radiological Health, formerly known as the Office of In Vitro Diagnostic Device Evaluation and Safety.
The FDA this week provided updates on the revamped Office of In Vitro Diagnostics & Radiological Health, formerly known as the Office of In Vitro Diagnostic Device Evaluation and Safety.
The Center for Devices & Radiological Health subsection will oversee in-home and laboratory diagnostic tests, radiological medical devices and radiation-emitting non-medical products, and will be responsible for implementing the Mammography Quality Program established federally in 1992.
The FDA further broke down the various sections with the ORI, defining their duties as follows:
Division of Chemistry and Toxicology Devices (DCTD)
- General chemistry tests
- Specialized chemistry tests including neonatal biochemical screening tests, endocrine tests, and tests for women's health
- Drug of abuse tests
- Therapeutic drug monitoring tests
- Minimally invasive and non-invasive tests
Division of Immunology and Hematology Devices (DIHD)
- Hematology, pathology, flow cytometry, and coagulation tests
- Tests for immunological disease
- Tumor marker (cancer detection) tests
- Genetic disorder (heritable somatic mutations) tests
Division of Microbiology Devices (DMD)
- Detection of microorganisms (bacteria, fungi, mycobacteria, viruses) by chemical, immunological, and nucleic acid amplification methods
- Biothreat agents
- New and emerging infectious diseases
Division of Radiological Health (DRH)News Well, 510(k), Food & Drug Administration (FDA), Pre-Market Approval (PMA), Regulatory/Compliance
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...